Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery
Microneedle (MN)-assisted drug delivery technology has gained increasing attention over the past two decades. Its advantages of self-management and being minimally invasive could allow this technology to be an alternative to hypodermic needles. MNs can penetrate the stratum corneum and deliver activ...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Journal of Pharmacy & Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | https://www.frontierspartnerships.org/articles/10.3389/jpps.2024.12434/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589664645545984 |
|---|---|
| author | Fanda Meng Xinyu Qiao Chenglong Xin Xiaoli Ju Meilin He |
| author_facet | Fanda Meng Xinyu Qiao Chenglong Xin Xiaoli Ju Meilin He |
| author_sort | Fanda Meng |
| collection | DOAJ |
| description | Microneedle (MN)-assisted drug delivery technology has gained increasing attention over the past two decades. Its advantages of self-management and being minimally invasive could allow this technology to be an alternative to hypodermic needles. MNs can penetrate the stratum corneum and deliver active ingredients to the body through the dermal tissue in a controlled and sustained release. Long-acting polymeric MNs can reduce administration frequency to improve patient compliance and therapeutic outcomes, especially in the management of chronic diseases. In addition, long-acting MNs could avoid gastrointestinal reactions and reduce side effects, which has potential value for clinical application. In this paper, advances in design strategies and applications of long-acting polymeric MNs are reviewed. We also discuss the challenges in scale manufacture and regulations of polymeric MN systems. These two aspects will accelerate the effective clinical translation of MN products. |
| format | Article |
| id | doaj-art-e22ab9e7ea76419db27dde6c3cd068bc |
| institution | Kabale University |
| issn | 1482-1826 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Journal of Pharmacy & Pharmaceutical Sciences |
| spelling | doaj-art-e22ab9e7ea76419db27dde6c3cd068bc2025-01-24T10:00:56ZengFrontiers Media S.A.Journal of Pharmacy & Pharmaceutical Sciences1482-18262024-03-012710.3389/jpps.2024.1243412434Recent progress of polymeric microneedle-assisted long-acting transdermal drug deliveryFanda Meng0Xinyu Qiao1Chenglong Xin2Xiaoli Ju3Meilin He4College of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, ChinaCollege of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, ChinaShandong Center for Disease Control and Prevention, Jinan, ChinaYantai Key Laboratory of Nanomedicine and Advanced Preparations, Yantai Institute of Materia Medica, Yantai, Shandong, ChinaYantai Key Laboratory of Nanomedicine and Advanced Preparations, Yantai Institute of Materia Medica, Yantai, Shandong, ChinaMicroneedle (MN)-assisted drug delivery technology has gained increasing attention over the past two decades. Its advantages of self-management and being minimally invasive could allow this technology to be an alternative to hypodermic needles. MNs can penetrate the stratum corneum and deliver active ingredients to the body through the dermal tissue in a controlled and sustained release. Long-acting polymeric MNs can reduce administration frequency to improve patient compliance and therapeutic outcomes, especially in the management of chronic diseases. In addition, long-acting MNs could avoid gastrointestinal reactions and reduce side effects, which has potential value for clinical application. In this paper, advances in design strategies and applications of long-acting polymeric MNs are reviewed. We also discuss the challenges in scale manufacture and regulations of polymeric MN systems. These two aspects will accelerate the effective clinical translation of MN products.https://www.frontierspartnerships.org/articles/10.3389/jpps.2024.12434/fullpolymericmicroneedlesdrug delivery systemstransdermallong-acting drug release |
| spellingShingle | Fanda Meng Xinyu Qiao Chenglong Xin Xiaoli Ju Meilin He Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery Journal of Pharmacy & Pharmaceutical Sciences polymeric microneedles drug delivery systems transdermal long-acting drug release |
| title | Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery |
| title_full | Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery |
| title_fullStr | Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery |
| title_full_unstemmed | Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery |
| title_short | Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery |
| title_sort | recent progress of polymeric microneedle assisted long acting transdermal drug delivery |
| topic | polymeric microneedles drug delivery systems transdermal long-acting drug release |
| url | https://www.frontierspartnerships.org/articles/10.3389/jpps.2024.12434/full |
| work_keys_str_mv | AT fandameng recentprogressofpolymericmicroneedleassistedlongactingtransdermaldrugdelivery AT xinyuqiao recentprogressofpolymericmicroneedleassistedlongactingtransdermaldrugdelivery AT chenglongxin recentprogressofpolymericmicroneedleassistedlongactingtransdermaldrugdelivery AT xiaoliju recentprogressofpolymericmicroneedleassistedlongactingtransdermaldrugdelivery AT meilinhe recentprogressofpolymericmicroneedleassistedlongactingtransdermaldrugdelivery |